Both in Diagnostics
Insight Molecular Diagnostics vs Myriad Genetics
Over the past year IMDX returned −56.0% and MYGN returned −27.0%; their daily moves had a correlation of 0.09.
IMDX −56.0% MYGN −27.0%Growth of $1, one year, split-adjusted
| Metric | IMDX | MYGN |
|---|---|---|
| Price | $2.74 | $6.04 |
| Market cap | $89.7M | $577.7M |
| Today | −4.20% | +3.25% |
| 1 month | −25.3% | +31.9% |
| 6 months | −40.2% | +20.1% |
| Year to date | −63.5% | −1.8% |
| 1 year | −54.4% | −24.9% |
| Revenue growth (YoY) | −53.9% | −10.5% |
| Gross margin | 65.7% | 66.6% |
| Net margin | −4711.3% | −22.7% |
| P/E (TTM) | — | — |
| Price / sales | 53.7× | 0.7× |
| Net cash | $17.8M | -$5.5M |
| Dividend yield | — | — |
| Volatility (60d) | 95.6% | 85.1% |
| Short % of float | 3.7% | 10.1% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).